BioStem Technologies, Inc.
BSEM
Positions held
Your positionsBSEM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $49.29M | Enterprise value | $41.38M | Trailing P/E | 3.00 | Forward P/E | 9.10 |
| PEG | — | Price / book | 1.70 | Beta | 0.50 | Dividend yield | 0.00% |
| Revenue growth | -27.9% | Earnings growth | — | Gross margin | 79.9% | Operating margin | -106.3% |
| Profit margin | -81.8% | ROE | -74.7% | ROA | -18.1% | Debt / equity | 0.04 |
| Current ratio | 0.98 | Free cash flow | $8.68M | Analyst recommendation | none | Mean target | $7.00 |
| 52w high | $8.40 | 52w low | $2.25 |
Quarterly
| 2026-Q2 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|
| Revenue | $7.9M | $10.5M | $11.0M |
| Op margin | -106.3% | 13.8% | 1.0% |
| Net income | -$9.0M | $0.8M | $0.0M |
| Gross margin | 61.3% | 88.5% | 93.8% |
| Gross profit | $4.8M | $9.3M | $10.3M |
| Operating income | -$8.4M | $1.4M | $0.1M |
- Revenue -25% vs prior quarter ($7.9M vs $10M).
- Gross margin 61.3% (was 88.5% prior quarter).
- Operating margin compressed to -106.3%.
Yearly (6y)
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue | $302M | $16.7M | $6.9M | $4.3M |
| Op margin | 10.3% | -46.6% | -68.1% | -37.0% |
| Net income | $31.9M | -$8.5M | -$7.2M | -$1.4M |
| Gross margin | 95.4% | 92.4% | 87.2% | 66.0% |
| Gross profit | $288M | $15.4M | $6.0M | $2.9M |
| Operating income | $31.2M | -$7.8M | -$4.7M | -$1.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
2026-10-01 · BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
2026-09-30 · BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-09-18 · BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
2026-09-04 · BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
2026-09-03 · BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-22 · BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
2026-08-18 · Sidoti Events, LLC's August Micro-Cap Virtual Conference
2026-08-14 · BioStem Technologies to Present at the Sidoti MicroCap Conference
2026-08-13 · BioStem Technologies Inc (BSEM) (Q2 2026) Earnings Call Highlights: Revenue Surges to $7. ...
2026-08-13 · BioStem Technologies Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns